Clair Obscur: Expedition 33 stormed The Game Awards 2025, winning all but two categories it was nominated in, including the main prize: Game of the Year. Sandfall Interactive's much-loved RPG won a ...

After you meet the mentioned criteria, head to the Continent and pan your map to the bottom-right corner to find a new island just southeast of Lumiere. The "Thank You" update is adding a lot of free ...

You can trust VideoGamer. Our team of gaming experts spend hours testing and reviewing the latest games, to ensure you're reading the most comprehensive guide possible. Rest assured, all imagery and ...

GameSpot may get a commission from retail offers. Clair Obscur: Expedition 33 has been one of 2025's breakout success stories in gaming, and it was developed on a relatively small budget, apparently.

Clair Obscur Expedition 33 distinguishes itself not only through conventional avenues of video game excellence and meaningful political relevance but also through unerring commitment to its central ...

Atraverse Medical also approaches first 2,000 successful clinical procedures using the company's innovative HOTWIRE™ radiofrequency (RF) guidewire. SAN DIEGO, Dec. 4, 2025 /PRNewswire/ -- Atraverse ...

Expeditions are ARC Raiders' take on resetting your account, also called a wipe or a prestige. The mechanic is a core tenet of progression in extraction shooters, and ARC not only has a lengthy list ...

“A for effort, C+ for execution,” features editor Christian Sebaugh said about the new version of Ford’s Expedition, represented at SUVOTY by the off-road-capable Tremor model. His sentiment largely ...

The Blue Oval is eager to capture sales from Chevrolet. It’s clear that significant time, effort, and investment were put into the 2025 Ford Expedition to help it steal some sales away from the Chevy ...

If you had told me that a debut double-A game from a studio of largely unknown developers would be one of the biggest contenders for the Game of the Year awards in 2025, as well as one of the best ...

Expedition Therapeutics is gearing up for a phase 2 trek with a $165 million series A that closed Oct. 9. The new funding will fuel the Bay Area biotech’s DPP1 inhibitor EXPD-101 as it ventures into a ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.